Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. Life Science Group Division, doing business as Bio Rad Laboratories, is a for-profit manufacturer of life science research and clinical diagnostic equipment that operates as a child entity of parent Bio-Rad Laboratories, Inc., delivering polymerase chain reaction systems, droplet digital PCR instruments, gel imaging systems, protein analysis platforms, reagents, and maintenance services to federal agencies on a full-and-open competitive basis without set-aside posture.

Bio-Rad Laboratories headquarters in Hercules, California manufactures and distributes advanced molecular biology instrumentation and consumables across 5,527 total federal awards (5,523 as prime, 4 as sub) spanning the past five years with combined potential value of $97.9 million and $77.5 million obligated. The company competes across 139 distinct federal customer agencies with no SBA certifications or set-aside designations. Primary NAICS codes include 334516 (Analytical Laboratory Instrument Manufacturing), 811212 (Other Electronic and Precision Equipment Repair and Maintenance), and 325411 (Biological Product Manufacturing), with PSC concentration in Laboratory Equipment and Supplies (2,397 awards) and Equipment Maintenance and Repair (728 awards).

Customer concentration is distributed across health and research agencies. The top five by award count—CDC Office of Acquisition Services (296 awards, $8.1 million), NIH National Cancer Institute (173 awards, $3.1 million), CDC Pittsburgh (150 awards, $6.3 million), NIH National Institute of Allergy and Infectious Diseases (146 awards, $2.2 million), and NIH National Institute of Environmental Health Sciences (137 awards, $2.7 million)—account for only 16 percent of awards. Top five by potential value reach 25 percent of dollars, led by CDC Office of Acquisition Services and CDC Pittsburgh; the Navy Bureau of Medicine and Surgery ($4 million across 97 awards) and FDA ($3.3 million across 113 awards) round out the value leaders. Award activity has declined from 76 in 2022 to 9 in 2026 year-to-date, reflecting normal seasonal variation in a portfolio dominated by small task orders.

Bio-Rad's federal contracting is anchored to a single-award $10 million Blanket Purchase Agreement with NIH Office of Logistics and Acquisition Operations (effective through December 31, 2026) covering operations and maintenance items—biological materials, blood products, chemicals, laboratory supplies, and medical/veterinary/surgical supplies—on a firm fixed-price basis. Task order activity under this BPA accounts for documented procurements of CFX Opus real-time PCR systems, QX600 and QX200 droplet digital PCR equipment with automated droplet generation, Bio-Plex cytokine screening panels, ChemiDoc imaging systems, gel imagers, chromatography systems, and comprehensive maintenance and support services. Historic BPAs HHSN263201500172B (145 task orders, $1.9 million) and HHSN263199800049653B (83 task orders, $995 thousand) also appear in the active portfolio. Delivery Order contract 123A9419D0001 (20 task orders, $2.2 million) for IQ-Check kits and pathogen detection instruments is placed by the Office of Administrative Services Procurement Management Branch supporting food safety operations. Task order ceiling values typically range from $11,305 to $59,999, with ultimate completion dates extending one to five years from award.

Recent representative prime work includes a $230.8 million CDC sole-source purchase order for Bio-Rad OPUS instruments for influenza and SARS-CoV-2 assay evaluation (September 2024); a $309.6 thousand VA sole-source award for a QX600 AutoDG system with consumables supporting genomic testing (August 2023); a $106.2 thousand USDA sole-source award for droplet digital PCR system delivery, installation, training, and support in Fort Collins, Colorado (September 2023); $63.2 thousand CDC awards for HIV diagnostic kits under PEPFAR (August 2024); and $99.3 thousand CDC maintenance service agreement for the National Wastewater Surveillance System laboratory (September 2024). Maintenance and support service agreements dominate the portfolio, ranging from $9.8 thousand to $137.4 thousand, addressing preventative maintenance, recalibration, operational qualification, on-site repair, and software subscriptions for existing Bio-Rad instrumentation across NIH institutes, CDC facilities, VA medical centers, DoD locations, and EPA research stations. Sub-award activity is minimal—three documented subs under Leidos, Inc. (June 2025, diagnostics and surveillance research), a NASA JSC contract (June 2024, ChemiDoc MP imaging system), and a prior-year Bio-Plex option (May 2024)—reflecting Bio-Rad's overwhelmingly prime contracting posture.

Twenty-three awards totaling $1.3 million in combined potential value face ultimate completion within the next twenty-four months, creating modest recompete exposure concentrated in maintenance and consumables orders. Activity trajectory shows steady annual volume (42–76 awards per year from 2022 through 2025) in small-dollar transactional procurements typical of distributed purchasing across NIH institutes and centers, VA networks, CDC divisions, and specialty agencies. Bio-Rad's federal footprint is characteristic of a large, established OEM supplier dominating vendor-specific equipment maintenance and original consumable replacements where sole-source or brand-name justifications support non-competitive procurement and where existing customer relationships and installed-base lock-in limit competitive alternatives.